Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.38
- Piotroski Score 4.00
- Grade Outperform
- Symbol (NBTX)
- Company Nanobiotix S.A.
- Price $4.88
- Changes Percentage (-1.41%)
- Change -$0.07
- Day Low $4.87
- Day High $5.13
- Year High $9.60
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 09/25/2024
- Fiscal Year End N/A
- Average Stock Price Target $12.00
- High Stock Price Target $12.00
- Low Stock Price Target $12.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.17
- Trailing P/E Ratio -4.87
- Forward P/E Ratio -4.87
- P/E Growth -4.87
- Net Income $-39,700,000
